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Abstract
The environmental factors that contribute to the development of autoimmune diseases are largely
unknown. Endemic pemphigus foliaceus in humans, known as Fogo Selvagem (FS) in Brazil, is
mediated by pathogenic IgG4 autoantibodies against desmoglein1 (Dsg1). Clusters of FS overlap
with those of leishmaniasis, a disease transmitted by sand fly (Lutzomyia longipalpis) bites. In this
study we show that salivary antigens from the sand fly, and specifically the LJM11 salivary
protein, are recognized by FS antibodies. Anti-Dsg1 monoclonal autoantibodies derived from FS
patients also cross-react with LJM11. Mice immunized with LJM11 generate anti-Dsg1
antibodies. Thus, insect bites may deliver salivary antigens that initiate a cross-reactive IgG4
antibody response in genetically susceptible individuals and lead to subsequent FS. Our findings
establish a clear relationship between an environmental, non-infectious antigen and the
development of potentially pathogenic autoantibodies in an autoimmune disease.
It is an accepted assumption that the interaction of unknown environmental factors with
susceptibility genes of the host ensues the immune system to react to self-antigens causing
an spectrum of autoimmune diseases (1). The common thread amongst autoimmune diseases
is the obscure etiology. Human organ specific autoimmune diseases targeting the skin
comprise the pemphigus group, where pathogenic IgG4-restricted, anti-epidermal
autoantibodies cause epidermal cell detachment that leads to blister formation (2). The
antigen recognized by these autoantibodies in PF is Dsg1. The idiopathic, non-endemic form
of PF is known worldwide, whereas an endemic variety, FS is seen in certain regions of
subtropical Brazil (3). FS shows similar clinical, histological and immunological features to
non-endemic PF, except for the unique epidemiology of FS. A case-control epidemiological
study of FS in Brazil suggested that certain living conditions and exposure to
hematophagous insect bites were risk factors of FS (4). Exposure to bites of three insects is
suspected to be linked to FS, Lutzomyia longipalpis (sand flies), reduviids (kissing bugs)
and simuliids (black flies). They are vectors of leishmaniasis, Chagas disease and
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onchocerciasis respectively. Moreover, the sera of a large number of these patients possess
anti-Dsg1 autoantibodies (5).
A recent study has demonstrated that not only IgM and IgG4 anti-Dsg1 autoantibodies are
detected in the sera of FS but also IgE (6). It is remarkable that IgG4 anti-Dsg1
autoantibodies are restricted and pathogenic in FS, however, it is completely unknown the
mechanisms involved in the emergence of these autoantibodies. The endemic nature of FS
and the circumstantial evidence presented above allow us to test the hypothesis that salivary
gland antigens from hematophagous insects are the source of sensitizing antigen that triggers
the autoimmune disease in FS. We selected a well-defined system provided by Lutzomyia
longipalpis, where the salivary gland proteins are well characterized (7, 8). In this
investigation we show that IgG4 and IgE autoantibodies from FS sera recognized salivary
gland antigens from Lutzomyia longipalpis (SGLL). The major SGLL antigenic component
recognized by FS sera is LJM11. Additionally, sera from mice immunized with LJM11 also
recognize human recombinant Dsg1. These results strongly support the notion that LJM11
induces cross-reactive antibodies in FS patients and experimental animals. This is the first
evidence that a non-infectious agent may trigger a human autoimmune disease via molecular
mimicry.
Materials and Methods
Serum samples and anti-Dsg1 monoclonal antibodies from FS patients
FS sera (N = 45) and two IgG4 anti-Dsg1 monoclonal antibodies (4E4 and 2D11) derived
from FS patients (9), were used. Sera from healthy donors (n = 43) from the University of
North Carolina blood bank were included as controls (HC-UNC). Ten sera from normal
donors living in Brazilian endemic areas of FS were also included in some of the studies
(HC-endemic). This study was approved by the Institutional review boards from universities
of North Carolina, Chapel Hill and Sao Paulo, Brazil. The H and L chains of 4E4 and 2D11
(9) were cloned into pComb3XSS vector and expressed in Top10 F’ cells (10). A GST-tag
was introduced to the 4E4 construct to increase the solubility of the recombinant 4E4 scFv,
and 4E4-GST scFv was produced and purified by Genscript (Piscataway, NJ). The 4E4-GST
scFv was not pathogenic when tested by passive transfer into neonatal mice (2) and the
dispase assay (11) using concentrations up to 30ug/dose and 5ug/ml of the antibody
respectively.
Recombinant Human Dsg1, Sand fly salivary gland extract, and sand fly salivary proteins
Recombinant Dsg1 was generated and purified as described (12). Salivary gland extracts
from Lutzomyia longipalpis (SGLL) and SGLL proteins LJM11, LJM17, and LJL143 were
generated at the Laboratory of Malaria and Vector Research, NIAID by Valenzuela (8, 13).
ELISA
IgE and IgG4 anti-Dsg1 and anti-SGLL ELISAs were conducted as described in previous
communications (6, 9, 14). The ELISA assay to detect IgG4 antibody activity against
LJM11, LJM17 and LJL143 SGLL proteins was also conducted as above with some
modifications. Stripwell Microplates (Corning, Lowell, MA) were coated with 50ng/well
with either LJM11, or LJM17, or LJL143 proteins. A 1:100 dilution of each of FS sera or
scFv 4E4 and 2D11 anti-Dsg1 monoclonal antibodies (50ng/ml) was added and incubated.
The bound IgG4 antibodies from serum samples or scFv antibodies were detected with anti-
human IgG4 HRP (Zymed, San Francisco, CA) or anti-HA HRP conjugate (Roche,
Indianapolis, IN), respectively. Anti-Dsg1 ELISA using SGLL recombinant proteins
immunized mouse sera was conducted according to regular anti-Dsg1 ELISA described
above with following modification. The mouse sera was diluted 1:500 and goat anti-mouse
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IgG (Fc fraction) HRP conjugate (Jackson ImmunoResearch, Carlsbad, CA) was used to
detect anti-Dsg1 antibodies from mouse sera.
Immunoprecipitation (IP)
Pan mouse IgG magnetic Dynabead (Invitrogen, Carlsbad, CA) was used for the IP
according to manufacturer’s instructions with modifications. Mouse anti-human IgG4 and
Mouse anti-GST tag monoclonal antibodies (Zymed, San Francisco, CA) were used for the
IP of sand fly salivary gland proteins LJM11, LJM17, and LJL143. All IPs were proceeded
in the TBS buffer containing 0.5% Tween-20 and 5mM CaCl2 (TBS-T-Ca), plus 0.1% BSA.
First the Dynabeads (20μl of slurry) were blocked with 0.1% BSA in TBS-T-Ca for 1 hour
at room temperature (RT) and incubated with mouse anti-GST (for 4E4-GST) or mouse anti-
human IgG4 (for serum samples) for 1 hour at RT, and then 4E4-GST or human serum
samples for 2 hours at RT. Finally Dynabeads were incubated with LJM11, LJM17, and
LJL143, respectively for 2 hours at RT. For IP using SGLL recombinant protein immunized
mouse sera, 2μl of each mouse serum samples were incubated with 450μl recombinant
Dsg1 cell culture supernatant for 2 hours at RT and then with 20μl of Dynabead slurry for 1
hour. Each IP sample was subjected to SDS-PAGE and subsequent Western Blot. The
membranes were probed with anti-His HRP (Qiagen, Valencia, CA) and the bands revealed
with chemiluminescent substrate (Pierce, Rockford, IL).
Statistical Analysis
Groups were compared by t-test. Correlation analysis was by the Pearson correlation.
Results and Discussion
FS patients have IgE and IgG4 antibodies against Lutzomyia longipalpis salivary gland
antigens
We have recently reported that FS patients possess significantly higher levels of IgE and
IgG4 anti-Dsg1 antibodies than control groups from non-endemic areas of Brazil and US
(6). It is possible that generation of these anti-Dsg1 autoantibodies maybe secondary to
exposure and sensitization to an environmental antigen(s). The sera from FS patients, and
healthy controls from US (HC-UNC) were tested for IgE and IgG4 antibody activity against
SGLL by ELISA. As shown in Figure 1A, the index values of IgE and IgG4 anti-SGLL
antibodies are significantly higher in FS patients (n=45) than HC-UNC controls (n=43)
(p<0.001). The IgG4 anti-SGLL antibody response in the FS group was significantly
correlated with both the IgG4 anti-Dsg1 [Pearson correlation, (r=0.56, p<0.0001) and IgE
anti-SGLL (r=0.58, p<0.0001)] (Figure 1B). These findings strongly suggest that the
generation of potentially pathogenic IgG4 anti-Dsg1 in FS may be associated with the
antigenic stimulation produced by salivary antigens from hematophagous insects.
The cross-reactivity of anti-Dsg1 antibodies to SGLL
To determine whether the anti-SGLL activity from FS sera is due to the cross-reactivity of
anti-Dsg1 autoantibodies, ELISA was performed with two scFv IgG4 monoclonal anti-Dsg1
antibodies derived from two FS patients (9) against SGLL antigens. As shown in Figure 2A,
both scFv recognize SGLL. To confirm the cross-reactivity of the two monoclonal anti-Dsg1
autoantibodies with anti-SGLL antibodies, a competition ELISA assay was employed using
human recombinant Dsg1 as an inhibitor of the binding of anti-SGLL antibodies to
immobilized SGLL antigen. As shown in Figure 2B, binding of both monoclonal antibodies
to SGLL are inhibited in a dose dependent manner by soluble Dsg1. These findings suggest
that the anti-SGLL antibody activity in FS patients is, at least in part, due to cross-reactivity
of the anti-Dsg1 autoantibodies.
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The LJM11 major immunogenic component of SGLL is recognized by FS sera and IgG4
monoclonal anti-Dsg1 antibodies
A large number of secreted proteins are present in Lutzomyia longipalpis saliva (7, 8, 13)
and, LJM11 and LJM17 are the two main antigens that incite antibody responses in humans.
Other salivary antigens such as the LJL143 are weakly recognized by humans (13). These
three recombinant proteins were chosen to determine whether they are recognized by IgG4
antibodies from FS patients and normal controls from either FS endemic regions (HC-
endemic) or from non-FS endemic region (HC-UNC). Ten serum samples from each group
were randomly selected and tested. As shown in Figure 3A, we found that the reactivity of
FS sera was consistently much stronger to LJM11 than to LJM17 and LJL143. In addition,
the level of anti-LJM11 antibodies from FS is significantly higher than healthy donors from
HC-endemic (t-test, p=0.00029) and HC-UNC (t-test, p=0.00013). These results show that
IgG4 antibodies from FS sera chiefly recognize the LJM11 component of SGLL.
We next tested the reactivity of 4E4 and 2D11 IgG4 anti-Dsg1 monoclonal antibodies
against LJM11, LJM17 and LJL143. As shown in Figure 3B, both monoclonal antibodies
bind strongly to LJM11, but weakly to LJM17 and LJL143. These findings are similar to
those observed when testing FS sera. To further confirm that these two monoclonal
antibodies cross-react to LJM11, an ELISA inhibition assay was conducted. A doses of
100μg/ml of recombinant Dsg1 incubated with these antibodies was able to inhibit 90% and
70% of the bindings of 4E4 and 2D11 to LJM11 respectively (Figure 3C). In addition, IP
using monoclonal antibody 4E4, and FS patient serum show that both react strongly to
LJM11 (~43kD), but weakly to LJM17 (~45kD) and LJL143 (~34kD) (Figure 4A). These
findings suggest that LJM11 is the main component of SGLL that triggers the IgG4 immune
response in humans that cross-react with Dsg1 autoantigen.
The binding of anti-Dsg1 monoclonal antibodies to LJM11 is conformational and Ca2+
dependent
Both 4E4 and 2D11 anti-Dsg1 monoclonal antibody failed to react with denatured LJM11,
LJM17, and LJL143 by Western blot analysis (data not shown), suggesting that 4E4
antibody binding to the SGLL is conformational. Since binding of pathogenic autoantibodies
to Dsg1 is conformational and Ca2+ dependent (15), we tested the reactivity of these two
antibodies to LJM11 in the presence of either Ca2+ or EDTA. As shown in Figure 4B the
binding of these monoclonal antibodies from FS patients to LJM11 is also Ca2+-dependent.
These results suggest that the epitopes recognized by FS sera on SGLL, like those on Dsg1,
are Ca2+ dependent and conformational.
Mice immunized with LJM11 produce anti-Dsg1 antibodies
If SGLL proteins introduced by sand fly bites induce antibodies that cross-react to both
human Dsg1 and LJM11 in humans, it is expected that mice immunize with LJM11 also
generate cross-reactive antibodies to human Dsg1. Anti-Dsg1 reactivity of the sera from
these mice and control mouse were test by ELISA. As shown in Figure 4C (left panel), sera
from all three mice immunized with LJM11 strongly react to human Dsg1. The Dsg1
reactivity of these mouse sera was also tested by IP. As shown in Figure 4C (right panel),
the serum from a mouse immunized with LJM11 antigen also immunoprecipitates human
Dsg1. Control serum and sera from mice immunized with LJM17 and LJL143 antigens do
not show reactivity. These findings further confirm that LJM11 is the major component in
SGLL that induces the cross-reactive antibodies in both human FS patients and experimental
mice.
It is unusual that a population of antibodies would develop cross-reactivity to two
evolutionarily distant molecules, the human Dsg1 and a sand fly salivary gland component.
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There is no amino acid sequence similarity between Dsg1 and LJM11 (data not shown). The
Ca2+-dependent interaction suggests that autoantibodies react with both molecules via
conformational, but not linear, epitopes. This could explain how two evolutionary distant
molecules can both be recognized by cross-reactive antibodies since conformational
epitopes of both molecules may be the same even though their linear structures do not show
significant homology.
Our findings are also in line with molecular mimicry as the mechanism for how
environmental factors induce autoimmune diseases (1, 16). Unlike infectious agents that
induce robust IgG immune response, the low dose of the antigens and the route of the
exposure (skin) introduced by insect bites predictably induces an IgE response (17). It is
known that endemic regions of FS in Brazil are heavily infested of sand flies, and
individuals living in these areas are constantly exposed to these pests. It is likely that these
individuals mount IgE and IgG4 responses to salivary antigens such as the LJM11 protein.
Similar antibody responses have been described in people undergoing constant bee stings or
during immunotherapy of allergic patients (18–21). It would be expected that those
genetically predisposed individuals (22) living in endemic areas of FS are constantly
exposed to sand fly bites (and be sensitized to salivary antigens, including the LJM11
protein), thus generating IgG4 and IgE anti-SGLL antibodies which, as shown in this
investigation, may cross-react with unique epitopes on the ectodomain of human Dsg1.
Epitope spreading, as previously reported (23), may be the underlying mechanism that leads
to the generation of a more diverse autoantibody response in FS. The cross-reactive
antibodies may comprise a complex population of non-pathogenic and perhaps pathogenic
antibodies. In this context, it would be feasible that certain FS IgG4 autoantibodies may
exhibit distinct epitope specificity with those IgG4 anti-SGLL antibodies that cross-react
with human Dsg1. It is clear however, that testing the pathogenicity of these cross-reactive
antibodies is open for further investigations. In summary, this investigation provides the first
direct evidence that a non-infectious environmental agent may play a significant role in the
initiation of an autoimmune disease via molecular mimicry.
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FS patients have high levels of anti-SGLL IgG4 and IgE antibodies. (A). Boxplot analysis of
the IgG4 and IgE responses in FS patients (n=45) and UNC healthy controls (n=43) against
SGLL antigens by ELISA. The index values are higher in the FS group than the HC-UNC
group. (B). Pearson correlation analysis between the IgG4 anti-SGLL and the IgG4 anti-
Dsg1 responses (upper panel) and the IgE anti-SGLL and IgG4 anti-SGLL responses (lower
panel) in the same donors of the FS group.
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The cross-reactivity of two IgG4 anti-Dsg1 monoclonal antibodies from FS to SGLL by
ELISA. (A). Both IgG4 anti-Dsg1 monoclonal antibodies (scFv 4E4 and scFv 2D11) react to
SGLL. (B). The binding of both monoclonal antibodies, 2D11 (left panel) and 4E4 (right
panel) to SGLL is inhibited by Dsg1 in a concentration dependent manner. These results
were repeated three times with similar results.
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IgG4 antibodies from FS patients and two IgG4 monoclonal anti-Dsg1 antibodies derived
from FS patients recognize LJM11, a protein component from SGLL. (A). The reactivity of
ten random-selected FS sera (top panel), is higher than donors from the HC-endemic
(middle panel) and HC-UNC donors (bottom panel) when tested by ELISA with three SGLL
main proteins, LJM11, LJM17, and LJL143. The reactivity is mainly with the LJM11
protein. The differences between the HC-endemic and HC-UNC by the student-t test is not
significant (p=0.3800). (B) The 4E4 and 2D11 IgG4 monoclonal anti-Dsg1 antibodies also
recognize the LJM11 component from SGLL. (C). The binding of both anti-Dsg1
monoclonal antibodies to LJM11 is inhibited by Dsg1 protein.
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FS autoantibodies recognize LJM11 and sera from mice immunized with LJM11 bind
human Dsg1. (A). The 4E4 anti-Dsg1 monoclonal antibody (lanes 1,2,3), and control
samples without 4E4 (lanes 4,5,6) [left panel], HC-UNC (lanes 7,8,9) and FS serum (lanes
10, 11, 12) [right panel] were tested by IP against LJM11, LJM17 and LJL143 antigens. The
LJM11 heavy band is precipitated by 4E4 anti-Dsg1 monoclonal antibody and FS serum.
(B). The reactions of 4E4 and 2D11 anti-Dsg1 monoclonal antibodies with LJM11 by
ELISA in the presence of 5mM Ca2+ (black columns) are significantly inhibited in the
presence of 5mM EDTA (white columns). (C). Three sera from mice immunized with
LJM11, show strong reactivity to human Dsg1 by ELISA as compared with sera from mice
immunized with LJM17 and LJL143 and control mice (left panel). The right panel shows
human Dsg1 (lane 1), a control murine serum (lane 2), mouse anti-LJM1 (lane 3), mouse
anti-LJM17 (lane 4) and mouse anti-LJL143 (lane 5) tested against human Dsg1 by IP. The
only serum that immunoprecipitates human Dsg1 is from mouse anti-LJM11.
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